Canntab Therapeutics Stock Price, News & Analysis
Company Description
Canntab Therapeutics (OTC Link: CTABF) is a publicly traded drug manufacturers - specialty & generic company in the Healthcare sector. The company has a market capitalization of $147.0K.
CTABF stock has declined 100.0% over the past year.
This page provides a comprehensive overview of CTABF stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.
Stock Performance
Canntab Therapeutics (CTABF) stock. Over the past 12 months, the stock has lost 100.0%. At a market capitalization of $147.0K, CTABF is classified as a micro-cap stock with approximately 38.9M shares outstanding.
Latest News
Canntab Therapeutics has 10 recent news articles. Of the recent coverage, 1 article coincided with positive price movement and 1 with negative movement. Key topics include management, private placement. View all CTABF news →
SEC Filings
Financial Highlights
Upcoming Events
Short Interest History
Days to Cover History
CTABF Company Profile & Sector Positioning
Canntab Therapeutics (CTABF) operates in the Drug Manufacturers - Specialty & Generic industry within the broader Healthcare sector and is listed on the OTC Link.
Investors comparing CTABF often look at related companies in the same sector, including Centr Brands (CNTRF), Xebra Brands (XBRAF), Pineapple Express Cannabis Co (PNXP), Viaderma (VDRM), and Cryomass Technologies Inc (CRYM). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate CTABF's relative position within its industry.